Anika Therapeutics, Inc. ANIK, a leader in products for tissue protection, healing, and repair, based on hyaluronic acid technology, today announced Anika Therapeutics S.r.l., its wholly owned subsidiary, has entered into a new, five-year exclusive U.S. distribution agreement with Misonix, Inc. MSON, which will distribute and sell Anika's Hyalomatrix^®—an FDA-approved, HA-based skin substitute. One of the numerous
products added to the Anika portfolio through its acquisition of Fidia Advanced Biopolymers (now Anika Therapeutics S.r.l.), Hyalomatrix is indicated for treatment of a wide range of acute and chronic wounds.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in